全球機械閥門市場：規模、佔有率和趨勢分析（2026-2032 年）

全球機械閥門市場報告（至2032年）

2025年全球機械閥門市場規模為2.479億美元。預計該市場將以1.2%的複合年成長率成長，到2032年達到2.694億美元。

本報告涵蓋全球機械心臟瓣膜市場，包括旨在複製天然心臟瓣膜功能的人工瓣膜。

分析包括銷售量、平均售價 (ASP)、治療次數、市場規模、市場佔有率、成長趨勢、到 2032 年的市場預測以及到 2022 年的歷史數據。

機械瓣膜的高耐久性以及瓣膜設計和生物相容性材料的持續技術進步是推動市場成長的主要因素。然而，終身抗凝血治療的需求、兒童應用受限、組織瓣膜耐久性的提高以及經導管瓣膜治療的快速發展，仍然限制市場的進一步成長。

市場概覽

全球機械瓣膜市場包括用於替換受損或病變心臟瓣膜的人工瓣膜裝置。這些裝置旨在為原本需要接受外科瓣膜置換術的患者提供長期的瓣膜功能。

市場細分以瓣膜類型分類，包括機械主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣。當長期耐用性是首要的臨床考慮因素時，機械瓣膜通常是首選。

與生物瓣膜相比，機械瓣膜在耐用性方面具有顯著優勢。由於機械瓣膜植入後很少需要更換，因此對於某些預期功能壽命超過生物瓣膜的患者而言，機械瓣膜是重要的選擇。

然而，由於患者和臨床醫生越來越傾向於選擇組織瓣膜以避免終身抗凝血治療，市場成長緩慢。組織瓣膜耐久性的持續提高，以及經導管瓣膜治療的普及，進一步削弱了對機械瓣膜的需求。

市場促進因素

高耐久性

與生物瓣膜相比，機械瓣膜的主要優勢在於其耐用性。機械瓣膜的設計使用壽命遠長於生物瓣膜，植入後很少需要更換。

組織瓣膜通常平均可以使用10到15年，之後需要更換。因此，雖然組織瓣膜適用於許多老年患者，但對於可能需要在一生中多次接受瓣膜置換術的年輕患者來說，它們並非理想之選。

對於那些將長期耐用性放在首位的患者而言，機械瓣膜仍然十分有用。這包括某些年輕成人以及能夠安全長期接受抗凝血治療的患者。儘管市場規模有限，但其耐用優勢仍支撐著穩定的需求。

技術進步

技術進步正在減緩機械閥門市場的下滑速度。其中一個最重要的發展領域是生物相容性聚合物和改良材料的應用。

機械瓣膜可能引發免疫反應，導致血栓形成。這正是患者植入後需要終身抗凝血治療的主要原因。近年來，材料技術的改進旨在提高機械瓣膜的生物相容性，並減少血栓形成。

未來，如果聚合物和表面技術能夠更有效地抑制免疫反應，機械瓣膜的主要限制因素可能會減少。這有望重新激發人們對機械瓣膜的興趣，並促進市場進一步成長。

閥門設計改進

機械瓣膜設計的進步也正在改善患者的治療效果。例如，與傳統的籠式球閥或傾斜盤式植入相比，雙葉瓣膜能提供更自然的血流。

改善動態可以降低血栓形成的影響，並有可能減少安全治療患者所需的抗凝血劑用量。這將提高患者的生活品質，並提高某些病患小組對機械瓣膜的接受度。

雖然這些設計改進並不能完全消除抗凝血治療的必要性，但它們有助於提高機械瓣膜的臨床評估效果。這支持了機械瓣膜的持續應用，即使在生物瓣膜和經導管治療面臨激烈市場競爭的情況下也是如此。

市場限制

抗凝血物

機械瓣膜市場的主要阻礙因素是患者需要終身抗凝血治療。接受機械瓣膜植入的患者需要在餘生中持續接受抗凝血治療。

當機械瓣膜損傷紅血球或血小板時，會形成血栓。這些血栓會阻塞血管，可能導致嚴重的併發症甚至死亡。為了降低這種風險，患者通常需要服用抗凝血藥物，例如Warfarin。

抗凝血治療需要定期進行血液檢查以確保患者安全。由於抗凝血劑會抑制血液凝固，如果患者出現出血，則有發生其他併發症的潛在風險。鑑於這種長期治療帶來的負擔，許多患者和臨床醫生在臨床條件允許的情況下傾向於選擇生物瓣膜置換術。

小兒科

機械心臟瓣膜在兒童患者中應用並不廣泛。主要問題在於機械瓣膜無法隨著兒童心臟的生長而增加。

隨著時間的推移，這可能導致患者與人工瓣膜不匹配，進而導致植入的瓣膜對於不斷生長的心臟而言太小。因此，隨著兒童患者的生長發育，他們可能需要再次手術更換瓣膜。

由於機械瓣膜可能需要多次手術，因此在兒童病例中通常並非首選。這限制了潛在患者群體。

生物瓣膜和經導管瓣膜的市佔率侵蝕

機械瓣膜市場正受到生物瓣膜性能提升和經導管治療普及的限制。生物瓣膜的耐用性日益增強，削弱了機械瓣膜的傳統優勢之一。

同時，經導管瓣膜治療的應用範圍正在擴大。這些手術具有微創的特點，因此對醫生和患者都越來越有吸引力。

隨著生物瓣膜和經導管瓣膜技術的進步，機械瓣膜面臨日益嚴峻的挑戰。因此，預計到2032年，機械瓣膜市場的成長將持續低迷。

市場覆蓋範圍和數據範圍

• 量化研究範圍：市場規模、市場佔有率、手術數量、市場預測、市場成長率、銷售單位數、平均售價。
• 定性範圍：市場促進因素和限制因素、競爭分析、近期併購、公司簡介、產品系列和主要競爭對手。
• 目標時期：基準年為 2025 年，預測至 2032 年，歷史資料截至 2022 年。
• 建立市場模型：收入分析採用銷售量和平均售價（ASP），並輔以治療量、競爭市場佔有率分析和預測假設。
• 目標設備：本報告涵蓋用於替換天然心臟瓣膜的機械瓣膜，包括主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣等機械瓣膜產品。

目標市場及區隔

機械閥門市場

本報告涵蓋了全球機械瓣膜市場，將其視為心臟外科醫療設備的一個領域。

機械瓣膜是人工瓣膜，旨在模擬天然心臟瓣膜的功能。當患者的天然瓣膜衰竭時，會在外科瓣膜置換術中使用機械瓣膜。

在市場細分中，機械瓣膜依瓣膜類型分為主動脈瓣膜、二尖瓣膜、肺動脈瓣膜和三尖瓣膜。

主動脈瓣和二尖瓣的機械瓣膜應用最成熟，而肺動脈瓣和三尖瓣的應用則較為有限。瓣膜的選擇取決於受累瓣膜、患者情況、預期耐久性要求以及對長期抗凝血治療的耐受性。

每個細分市場都以市場規模、市場佔有率、手術數量、市場預測、市場成長率、銷售量和平均售價進行分析。

這種市場細分使製造商、投資者和策略團隊能夠了解瓣膜類型、患者選擇、耐用性要求以及相互競爭的外科手術和經導管治療方案如何塑造全球機械瓣膜市場。

競爭分析

2025年，雅培是全球機械閥市場的主要企業。該公司提供尺寸從19毫米到29毫米的Masters HP™和Regent™機械閥。

雅培的Masters HP™瓣膜也提供15毫米規格，適用於兒童手術。這使得公司能夠提供更廣泛的尺寸選擇，以滿足特定的臨床需求，但由於患者數量不斷增加以及再次手術的需求等挑戰，兒童領域的應用仍然有限。

機械瓣膜市場的相對重要性正在下降，導致活躍的競爭對手數量有限。由於雅培公司專注於快速成長的心臟器械市場，其市場佔有率在預測期內可能會下降。

Artivion是全球機械瓣膜市場第二大競爭對手。該公司提供Conform-X™、Anatomic™和Standard™三種機械瓣膜。其產品系列有限且專業化，使該公司能夠專注於機械瓣膜的關鍵患者群體。

Corcym是市面上的第三大廠商。其Carbomedics™系列機械瓣膜可用於主動脈瓣和二尖瓣置換術，尺寸從19毫米到33毫米不等。由於Corcym已縮減產品系列，預計在預測期內，隨著擁有更廣泛商業模式的競爭對手優先發展成長更快的市場，Corcym的市場佔有率將略有成長。

技術和臨床趨勢

生物相容性材料

生物相容性材料是機械瓣膜市場的關鍵發展領域。它們的目標是減輕導致血栓形成的免疫反應。

材料的改進可能會減少對強化抗凝血治療的需求，而強化抗凝血治療是機械瓣膜普及應用的最大障礙。

雙尖瓣設計

與傳統的籠球式或傾斜盤式設計相比，二葉式機械瓣膜可提供更自然的血液流動。

這種設計改進降低了血栓形成的影響，並提高了患者的耐受性，使得某些患者群體能夠繼續使用機械瓣膜。

優先考慮患者抗藥性的選擇

對於需要長期使用瓣膜的患者而言，機械瓣膜仍是最適合的選擇。這包括年輕成人以及瓣膜重新置換會帶來顯著臨床風險的患者。

即使生物瓣膜的市場佔有率不斷擴大，基於耐用性的患者選擇仍將繼續支撐市場需求。

生物瓣膜耐久性所帶來的壓力

目前，生物瓣膜的使用壽命比以往更長。隨著生物瓣膜耐久性的提高，機械瓣膜使用壽命長的優勢對許多患者而言已不再是決定性因素。

這一趨勢對老年患者來說尤其重要，因為這可能意味著組織瓣膜的壽命足以讓他們安享晚年。

經導管治療的擴展

經導管瓣膜置換療法正在改變瓣膜置換市場。其微創特性使其成為患者、醫生，尤其是高風險和老年患者的理想選擇。

隨著符合經導管輔助治療條件的患者群體擴大，對外科機械瓣膜的需求預計將保持低迷。

集中競爭組合

與其他許多心臟器械領域相比，機械瓣膜市場的主要競爭對手較少。由於大型競爭對手專注於快速發展的結構性心臟病治療技術，因此專注於特定瓣膜產品線的公司在維持市場佔有率方面被認為具有優勢。

這為那些繼續專注於機械閥門產品線的專業公司創造了商機。

地區

本報告涵蓋全球調查區域，包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

這份報告的意義

• 全球機械閥門市場目前的規模有多大？預計到 2032 年將成長多少？
• 隨著時間的推移，銷售量、治療量、平均售價（ASP）和市場規模發生了什麼樣的變化？
• 機械閥門市場包含哪些類型的閥門？
• 主動脈瓣、二尖瓣、肺動脈瓣和三尖瓣的用途有何不同？
• 為什麼耐用性仍然是機械閥的主要優勢？
• 抗凝血治療的要求對病人和醫師的選擇有哪些限制？
• 生物相容性聚合物和改進的閥門設計將在未來的市場潛力中發揮怎樣的作用？
• 組織瓣膜和經導管瓣膜治療的改進對機械瓣膜的需求產生了怎樣的影響？
• 哪家公司在全球機械閥門市場佔有領先地位？
• Abbott、Artivion 和 Corcym 在競爭格局中處於什麼位置？

iData Research 的《全球機械閥市場報告》透過設備層級分析、基於技術的建模、平均售價 (ASP) 數據、企業市場占有率分析以及到 2032 年的預測來解答這些問題。該報告可用於評估需求、比較競爭對手、了解閥門技術趨勢，並為全球機械閥市場的產業計畫提供支援。

目錄

調查方法

• 第一步：專案啟動與團隊組建
• 步驟 2：準備資料系統並進行二次調查。
• 步驟 3：設計和準備訪談和調查問卷。
• 第四步：進行初步調查
• 第五步：調查與分析：建立基準估計值
• 第六步：市場預測與分析
• 步驟 7：辨識策略機遇
• 步驟 8：最終審核和市場推廣
• 步驟九：客戶回饋與市場監測

全球關稅的影響

機械閥門市場

• 執行摘要
  • 全球機械閥市場概覽
  • 競爭分析
  • 目標程式
  • 目標區域
• 介紹
• 手術次數
  • 完全機械瓣膜置換術
  • 機械主動脈瓣膜手術
  • 二尖瓣機械瓣膜手術
  • 三尖瓣機械瓣膜手術
  • 肺動脈機械瓣膜手術
• 市場分析與預測
• 促進因素和抑制因素
• 競爭性市佔率分析

附錄

Global Mechanical Heart Valve Market Report to 2032

The global mechanical heart valve market was valued at $247.9 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.2%, reaching $269.4 million by 2032.

This report covers the global market for mechanical heart valves, including prosthetic devices designed to replicate the function of the natural valves of the human heart.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by the high durability of mechanical valves and ongoing technological advancements in valve design and biocompatible materials. However, lifelong anticoagulation requirements, limited pediatric use, improving tissue valve durability, and the rapid expansion of transcatheter valve therapies continue to limit stronger market expansion.

Market Overview

The global mechanical heart valve market includes prosthetic devices used to replace damaged or diseased heart valves. These devices are designed to provide long-term valve function in patients who require surgical valve replacement.

The market is segmented by valve type, including aortic, mitral, pulmonary, and tricuspid mechanical valves. Mechanical valves are most often selected when long-term durability is the main clinical priority.

Mechanical heart valves have a major durability advantage over tissue valves. Once implanted, mechanical valves rarely require replacement, making them an important option for certain patients who are expected to outlive the functional lifespan of a tissue valve.

However, the market is growing slowly because both patients and clinicians increasingly favor tissue valve options to avoid lifelong anticoagulation therapy. Ongoing improvements in tissue valve durability, along with the expansion of transcatheter valve therapies, continue to cannibalize demand for mechanical heart valves.

Market Drivers

High Durability

The main advantage of mechanical valves over tissue heart valves is durability. Mechanical valves are designed to last much longer than tissue valves and rarely require replacement once implanted.

Tissue valves typically last 10 to 15 years on average before replacement may be needed. This makes tissue valves suitable for many older patients, but less ideal for younger patients who may require multiple valve replacement procedures over their lifetime.

Mechanical valves remain relevant for patients where long-term durability is the top priority. This includes certain younger adults and patients who can safely manage long-term anticoagulation therapy. Although the market is limited, this durability advantage continues to support stable demand.

Technological Advancements

Technological advancements are helping slow the decline of the mechanical heart valve market. One of the most important areas of development is the use of biocompatible polymers and improved materials.

Mechanical valves can trigger an immune response, which contributes to blood clot formation. This is the main reason patients need lifelong anticoagulation therapy after implantation. Newer material improvements are intended to make mechanical valves more biocompatible and reduce clot formation.

If future polymers or surface technologies can prevent the immune response more effectively, the main limitation of mechanical valves could be reduced. This would create renewed interest in mechanical valves and could support stronger market growth.

Improved Valve Design

Advancements in mechanical valve design have also improved patient outcomes. Bi-leaflet valves, for example, provide more natural blood flow than older caged-ball or tilting-disc implants.

Improved blood flow dynamics can reduce clotting effects and may reduce the amount of blood thinner needed to manage patients safely. This can improve quality of life and make mechanical valves more acceptable to select patient groups.

While these design improvements have not eliminated the need for anticoagulation, they have helped improve the clinical profile of mechanical valves. This has supported continued use in a market facing strong competition from tissue valves and transcatheter therapies.

Market Limiters

Anticoagulants

The main limiter of the mechanical heart valve market is the need for lifelong anticoagulation therapy. Patients with mechanical valves require consistent anticoagulant treatment for the rest of their lives.

Clots can form when red blood cells and platelets are damaged by the mechanical valve. These clots can block blood vessels and lead to serious complications or death. To reduce this risk, patients commonly require anticoagulants such as warfarin.

Anticoagulation therapy also requires regular blood testing for patient safety. It can create additional risks if the patient experiences bleeding, because anticoagulants inhibit clotting. This long-term treatment burden makes many patients and clinicians prefer tissue valves when clinically appropriate.

Pediatrics

Mechanical heart valves are generally not widely used in pediatric patients. The main challenge is that mechanical valves do not grow as a child's heart grows.

This can lead to patient-prosthesis mismatch over time, where the implanted valve becomes too small for the growing heart. As a result, pediatric patients may require repeat surgeries to replace the valve as they grow.

Because multiple operations may be necessary, mechanical valves are often not the preferred option in pediatric cases. This limits the potential patient base for the market.

Cannibalization from Tissue and Transcatheter Valves

The mechanical heart valve market is being constrained by improvements in tissue heart valves and the expansion of transcatheter therapies. Tissue valves have become more durable over time, reducing one of the historical advantages of mechanical valves.

At the same time, transcatheter valve therapies are expanding across broader patient populations. These procedures offer less invasive treatment options, which are increasingly attractive to both physicians and patients.

As tissue and transcatheter valves continue to improve, mechanical valves face increasing pressure. This is expected to keep growth modest through 2032.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers mechanical heart valves used to replace natural heart valves, including aortic, mitral, pulmonary, and tricuspid mechanical valve products.

Markets Covered and Segmentation

Mechanical Heart Valve Market

The report covers the global mechanical heart valve market as a dedicated segment within cardiac surgery devices.

Mechanical heart valves are prosthetic devices designed to replicate the function of natural heart valves. They are used in surgical valve replacement procedures when a patient's native valve is no longer functioning properly.

The market is segmented by valve type into aortic, mitral, pulmonary, and tricuspid mechanical valves.

Aortic and mitral mechanical valves represent the most established areas of use, while pulmonary and tricuspid applications are more limited. Selection depends on the affected valve, patient profile, expected durability needs, and tolerance for long-term anticoagulation therapy.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how valve type, patient selection, durability requirements, and competing surgical and transcatheter options are shaping the global mechanical heart valve market.

Competitive Analysis

Abbott was the leading competitor in the global mechanical heart valve market in 2025. The company offers its Masters HP(TM) and Regent(TM) mechanical heart valves, with available sizes ranging from 19 mm to 29 mm.

Abbott's Masters HP(TM) valve also includes a 15-mm option for pediatric surgery. This provides the company with a broader size range for select clinical needs, although the pediatric segment remains limited by the challenge of patient growth and repeat surgery requirements.

The mechanical heart valve market is contracting in relative importance, which has resulted in a limited number of active competitors. Abbott may lose some share over the forecast period as the company shifts focus toward faster-growing cardiac device markets.

Artivion was the second-leading competitor in the global mechanical heart valve market. The company offers the Conform-X(TM), Anatomic(TM), and Standard(TM) mechanical heart valves. Its limited and focused portfolio allows it to concentrate on the core patient pool for mechanical valves.

Corcym was the third-leading company in the market. Its Carbomedics(TM) line of mechanical valves is available for aortic and mitral valve replacement, with sizes ranging from 19 mm to 33 mm. Because Corcym maintains a focused heart valve portfolio, it is expected to gain some share over the forecast period as broader competitors prioritize larger growth markets.

Technology and Practice Trends

Biocompatible Materials

Biocompatible materials are an important area of development in the mechanical heart valve market. The goal is to reduce the immune response that contributes to clot formation.

Improved materials may help reduce the need for intensive anticoagulation therapy, which remains the largest barrier to mechanical valve adoption.

Bi-Leaflet Valve Design

Bi-leaflet mechanical valves provide more natural blood flow than older caged-ball or tilting-disc designs.

This design improvement has helped reduce clotting effects and improve patient tolerance, supporting continued use of mechanical valves in select patient groups.

Durability-Focused Patient Selection

Mechanical valves remain most relevant for patients who need long-lasting valve performance. This includes younger adults and patients for whom repeat valve replacement would create significant clinical risk.

Durability-focused selection will continue to support demand, even as tissue valves gain share.

Pressure from Tissue Valve Durability

Tissue valves now last longer than they did historically. As tissue valve durability improves, the advantage of mechanical valve longevity becomes less decisive for many patients.

This trend is especially important for older patients, where tissue valve lifespan may be sufficient for the remainder of life.

Expansion of Transcatheter Therapies

Transcatheter valve therapies are reshaping the valve replacement market. Their less invasive nature makes them attractive to patients and physicians, particularly for high-risk and older patients.

As transcatheter therapies expand into broader patient groups, they are expected to continue limiting surgical mechanical valve demand.

Focused Competitive Portfolios

The mechanical heart valve market has fewer major competitors than many other cardiac device segments. Companies with focused valve portfolios may be better positioned to maintain share as larger competitors prioritize faster-growing structural heart technologies.

This creates opportunities for specialized companies that remain committed to mechanical valve product lines.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global mechanical heart valve market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• Which valve types are included in the mechanical heart valve market?
• How do aortic, mitral, pulmonary, and tricuspid mechanical valve applications differ?
• Why does durability remain the main advantage of mechanical heart valves?
• How are anticoagulation requirements limiting patient and physician preference?
• What role do biocompatible polymers and improved valve designs play in future market potential?
• How are tissue valve improvements and transcatheter valve therapies affecting mechanical valve demand?
• Which companies lead the global mechanical heart valve market?
• How are Abbott, Artivion, and Corcym positioned in the competitive landscape?

The Global Mechanical Heart Valve Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand valve technology trends, and support commercial planning in the global mechanical heart valve market.

TABLE OF CONTENT

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

Mechanical Heart Valve Market

• 6.1 Executive Summary
  • 6.1.1 Global Mechanical Heart Valve Market Overview
  • 6.1.2 Competitive Analysis
  • 6.1.3 Procedures Included
  • 6.1.4 Regions Included
• 6.2 Introduction
• 6.3 Procedure Numbers
  • 6.3.1 Total Mechanical Heart Valve Procedures
  • 6.3.2 Aortic Mechanical Heart Valve Procedures
  • 6.3.3 Mitral Mechanical Heart Valve Procedures
  • 6.3.4 Tricuspid Mechanical Heart Valve Procedures
  • 6.3.5 Pulmonary Mechanical Heart Valve Procedures
• 6.4 Market Analysis And Forecast
• 6.5 Drivers And Limiters
  • 6.5.1 Market Drivers
  • 6.5.2 Market Limiters
• 6.6 Competitive Market Share Analysis

Appendix

LIST OF CHARTS

• Chart 6-1: Mechanical Heart Valve Market, Global, 2025 & 2032
• Chart 6-2: Mechanical Heart Valve Procedures, Global, 2025
• Chart 6-3: Mechanical Heart Valve Procedures by Segment, Global, 2022 - 2032
• Chart 6-4: Mechanical Heart Valve Market, Global, 2022 - 2032
• Chart 6-5: Leading Competitors, Mechanical Heart Valve Market, Global, 2025

LIST OF FIGURES

• Figure 6-1: Mechanical Heart Valve Procedures Covered
• Figure 6-2: Mechanical Heart Valve Regions Covered, Global (1 of 2)
• Figure 6-3: Mechanical Heart Valve Regions Covered, Global (2 of 2)
• Figure 6-4: Mechanical Heart Valve Procedures by Segment, Global, 2022 - 2032
• Figure 6-5: Mechanical Heart Valve Procedures by Region, Global, 2022 - 2032
• Figure 6-6: Mechanical Heart Valve Procedures by Country, North America, 2022 - 2032
• Figure 6-7: Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-8: Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-9: Mechanical Heart Valve Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-10: Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-11: Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-12: Mechanical Heart Valve Procedures by Country, Middle East, 2022 - 2032
• Figure 6-13: Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-14: Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-15: Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-16: Mechanical Heart Valve Procedures by Country, Africa, 2022 - 2032
• Figure 6-17: Aortic Mechanical Heart Valve Procedures by Region, Global, 2022 - 2032
• Figure 6-18: Aortic Mechanical Heart Valve Procedures by Country, North America, 2022 - 2032
• Figure 6-19: Aortic Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-20: Aortic Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-21: Aortic Mechanical Heart Valve Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-22: Aortic Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-23: Aortic Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-24: Aortic Mechanical Heart Valve Procedures by Country, Middle East, 2022 - 2032
• Figure 6-25: Aortic Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-26: Aortic Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-27: Aortic Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-28: Aortic Mechanical Heart Valve Procedures by Country, Africa, 2022 - 2032
• Figure 6-29: Mitral Mechanical Heart Valve Procedures by Region, Global, 2022 - 2032
• Figure 6-30: Mitral Mechanical Heart Valve Procedures by Country, North America, 2022 - 2032
• Figure 6-31: Mitral Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-32: Mitral Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-33: Mitral Mechanical Heart Valve Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-34: Mitral Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-35: Mitral Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-36: Mitral Mechanical Heart Valve Procedures by Country, Middle East, 2022 - 2032
• Figure 6-37: Mitral Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-38: Mitral Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-39: Mitral Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-40: Mitral Mechanical Heart Valve Procedures by Country, Africa, 2022 - 2032
• Figure 6-41: Tricuspid Mechanical Heart Valve Procedures by Region, Global, 2022 - 2032
• Figure 6-42: Tricuspid Mechanical Heart Valve Procedures by Country, North America, 2022 - 2032
• Figure 6-43: Tricuspid Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-44: Tricuspid Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-45: Tricuspid Mechanical Heart Valve Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-46: Tricuspid Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-47: Tricuspid Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-48: Tricuspid Mechanical Heart Valve Procedures by Country, Middle East, 2022 - 2032
• Figure 6-49: Tricuspid Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-50: Tricuspid Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-51: Tricuspid Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-52: Tricuspid Mechanical Heart Valve Procedures by Country, Africa, 2022 - 2032
• Figure 6-53: Pulmonary Mechanical Heart Valve Procedures by Region, Global, 2022 - 2032
• Figure 6-54: Pulmonary Mechanical Heart Valve Procedures by Country, North America, 2022 - 2032
• Figure 6-55: Pulmonary Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (1 of 2)
• Figure 6-56: Pulmonary Mechanical Heart Valve Procedures by Country, Latin America, 2022 - 2032 (2 of 2)
• Figure 6-57: Pulmonary Mechanical Heart Valve Procedures by Country, Western Europe, 2022 - 2032
• Figure 6-58: Pulmonary Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (1 of 2)
• Figure 6-59: Pulmonary Mechanical Heart Valve Procedures by Country, Central & Eastern Europe, 2022 - 2032 (2 of 2)
• Figure 6-60: Pulmonary Mechanical Heart Valve Procedures by Country, Middle East, 2022 - 2032
• Figure 6-61: Pulmonary Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (1 of 3)
• Figure 6-62: Pulmonary Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (2 of 3)
• Figure 6-63: Pulmonary Mechanical Heart Valve Procedures by Country, Asia-Pacific, 2022 - 2032 (3 of 3)
• Figure 6-64: Pulmonary Mechanical Heart Valve Procedures by Country, Africa, 2022 - 2032
• Figure 6-65: Mechanical Heart Valve Market, Global, 2022 - 2032
• Figure 6-66: Units Sold by Region, Mechanical Heart Valve Market, Global, 2022 - 2032
• Figure 6-67: Average Selling Price by Region, Mechanical Heart Valve Market, Global, 2022 - 2032 (US$)
• Figure 6-68: Market Value by Region, Mechanical Heart Valve Market, Global, 2022 - 2032 (US$M)
• Figure 6-69: Leading Competitors, Mechanical Heart Valve Market, Global, 2025